Inion signs research agreement with Angiomed to develop biodegradable peripheral vascular stents

By Lisa Kerner

Erie, Pa., Mary 15 - Inion Oy signed a cooperation and research agreement with Angiomed GmbH & Co Medizintechnik KG, a Germany-based subsidiary of life sciences products group C.R. Bard Inc., to develop biodegradable peripheral vascular stents as an alternative to metal stents.

Unlike metal stents, biodegradable stents leave the blood vessel or organ free of any prosthetic remains, according to a company news release.

Applications for these biodegradable prostheses include vascular, urinary, biliary, renal and esophageal stents, as well as urological catheterization.

Under the agreement, Angiomed will pay upfront and milestone payments for the feasibility phase of the project. Both companies will jointly own any intellectual property created.

No further financial details of the agreement were disclosed.

"Inion's Optima technology is already well established in orthopaedic and dental applications and this is the first time we have entered into a collaboration agreement to target another clinical area," Inion chairman and chief executive officer Auvo Kaikkonen said in the release.

Inion, located in Tampere, Finland, specializes in the development of biodegradable medical implants.

C. R. Bard, based in Murray Hill, N.J., develops, manufactures and markets medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.